DRUGS giant AstraZeneca and the Medical Research Council will today announced that they are building a new research and development centre in Cambridge, to better understand a range of human diseases.
AstraZeneca offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results